Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.

被引：2
作者：
Tamura, Kenji
Hashimoto, Jun
Tsuda, Hitoshi
Yoshida, Masayuki
Yamauchi, Hideko
Aogi, Kenjiro
Shimizu, Satoru
Iwata, Hiroji
Masuda, Norikazu
Yamamoto, Naohito
Inoue, Kenichi
Ohno, Shinji
Kuroi, Katsumasa
Sukigara, Tamie
Fujiwara, Yasuhiro
Andoh, Masashi
机构：
[1] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Breast, Tokyo, Japan
[3] Natl Canc Ctr, Div Med Oncol, Tokyo, Japan
[4] Natl Def Med Coll, Dept Basic Pathol, Tokorozawa, Saitama 359, Japan
[5] Natl Canc Ctr, Dept Pathol & Labs, Tokyo, Japan
[6] St Lukes Int Hosp, Dept Breast Surg Oncol, Tokyo, Japan
[7] NHO Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan
[8] Kanagawa Canc Ctr, Dept Breast Oncol & Endocrine Surg, Yokohama, Kanagawa, Japan
[9] Aichi Canc Ctr, Dept Breast Oncol, Nagoya, Aichi 464, Japan
[10] NHO Osaka Natl Hosp, Dept Surg, Breast Oncol, Osaka, Japan
[11] Chiba Canc Ctr, Chiba 2608717, Japan
[12] Saitama Canc Ctr, Div Breast Oncol, Saitama, Japan
[13] Kyushu Natl Canc Ctr, Dept Clin Oncol, Fukuoka, Japan
[14] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[15] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Tokyo, Japan
[16] Natl Canc Ctr, Tokyo, Japan
[17] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1017
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer
    Cancello, Giuseppe
    Bagnardi, Vincenzo
    Sangalli, Claudia
    Montana, Emilia
    Dellapasqua, Silvia
    Sporchia, Andrea
    Iorfida, Monica
    Viale, Giuseppe
    Barberis, Massimo
    Veronesi, Paolo
    Luini, Alberto
    Intra, Mattia
    Goldhirsch, Aron
    Colleoni, Marco
    CLINICAL BREAST CANCER, 2015, 15 (04) : 259 - 265
  • [22] A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer
    Yardley, Denise A.
    Shipley, Dianna
    Zubkus, John
    Wright, Gail L.
    Ward, Patrick J.
    Mani, Aruna
    Shastry, Mythili
    Finney, Lindsey
    DeBusk, Laura
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2019, 19 (01) : 1 - 9
  • [23] Neoadjuvant 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
    Heller, W.
    Mazhar, D.
    Ward, R.
    Lowdell, C.
    Dudley, S.
    Sami, S.
    Carlo, P.
    Charles, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S157 - S157
  • [24] Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.
    Matsuda, Naoko
    Alvarez, Ricardo H.
    Krishnamurthy, Savitri
    Willey, Jie S.
    Wang, Xiaoping
    Lim, Bora
    Parker, Charla A.
    Marx, Angela
    Babiera, Gildy
    Booser, Daniel J.
    Murray, James L.
    Arun, Banu
    Brewster, Abenaa M.
    Reuben, James M.
    Woodward, Wendy A.
    Lucci, Anthony
    Gainer, Sarah Marie
    Tripathy, Debu
    Valero, Vicente
    Ueno, Naoto T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Neoadjuvant chemotherapy with a dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer.: A phase II and pharmacogenomic study.
    Sánchez-Rovira, P
    Sánchez, A
    Ribelles, A
    Dueñas, B
    Cidraque, M
    Dueñas, R
    Jaén, A
    Martinez, E
    Medina, B
    Carrasco, E
    Lozano, A
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S108 - S109
  • [26] Dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab as neoadjuvant chemotherapy in stage II and III breast cancer.: A phase II and pharmacogenomic study.
    Sanchez-Rovira, P
    Duenas, B
    Cidraque, M
    Duenas, R
    Jaen, A
    Sanchez, A
    Martinez, E
    Medina, B
    Carrasco, E
    Lozano, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 29S - 29S
  • [27] Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel plus cyclophosphamide plus capecitabine followed by 5-fluorouracil plus epirubicin plus cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study)
    Higaki, Kenji
    Masuda, Norikazu
    Takano, Toshimi
    Matsunami, Nobuki
    Morimoto, Takashi
    Ohtani, Shoichiro
    Mizutani, Makiko
    Miyamoto, Takeshi
    Kuroi, Katsumasa
    Ohno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Phase IB study of primary chemotherapy with paclitaxel, gemcitabine, and sunitinib in patients with HER2-negative stage II/III breast cancer.
    Lee, K. S.
    Park, I.
    Ro, J.
    Kang, H. S.
    Kim, S. W.
    Lee, S.
    Jung, S. Y.
    Kwon, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
    Kodera, A.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Sakaguchi, S.
    Yukawa, H.
    Matsuoka, A.
    Tanaka, N.
    Kamimura, M.
    Jibiki, N.
    Fujibayasi, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [30] A phase II trial of the combination of S-1 and paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (FEC) as preoperative treatment inwomen with HER2-negative, stage II/III breast cancer
    Takahashi, Y.
    Jinno, H.
    Yoshikawa, M.
    Matsumoto, A.
    Ikeda, T.
    BREAST, 2017, 32 : S82 - S82
12345